Different Plasma Ghrelin Levels after Laparoscopic Gastric Bypass ...

3 downloads 0 Views 118KB Size Report
In fact, laparoscopic bariatric surgery is an increas- ing and effective treatment for morbid obesity (14 –17), yield- ing satisfactory long-term results in weight loss ...
0021-972X/03/$15.00/0 Printed in U.S.A.

The Journal of Clinical Endocrinology & Metabolism 88(9):4227– 4231 Copyright © 2003 by The Endocrine Society doi: 10.1210/jc.2003-030133

Different Plasma Ghrelin Levels after Laparoscopic Gastric Bypass and Adjustable Gastric Banding in Morbid Obese Subjects FRIDA LEONETTI, GIANFRANCO SILECCHIA, GIANLUCA IACOBELLIS, MARIA CRISTINA RIBAUDO, ALESSANDRA ZAPPATERRENO, CLAUDIO TIBERTI, CONCETTA VALERIA IANNUCCI, NICOLA PERROTTA, VINCENZO BACCI, MARIA SOLE BASSO, NICOLA BASSO, AND UMBERTO DI MARIO Division of Endocrinology (F.L., G.I., M.C.R., A.Z., C.T., C.V.I., U.D.M.), Departments of Clinical Sciences, Surgery P. Stefanini (G.S., N.P., M.S.B., N.B.), and Dietology (V.B.), University “La Sapienza,” Rome, Italy 00161 Gastric bypass has been reported to be associated with markedly suppressed plasma ghrelin levels, suggesting that it is one of the possible weight-reducing factors related to this procedure. The aim of this study was the evaluation of plasma ghrelin levels in patients who had undergone laparoscopic Roux-en-Y gastric bypass (LRYGBP) and laparoscopic adjustable silicone gastric banding (LASGB). Normoweight, obese subjects and patients who had undergone total gastrectomy were used as controls. In this cross-sectional study, we selected 10 subjects who underwent LASGB, 11 subjects with LRYGBP, 10 obese subjects, eight patients with total gastrectomy, and eight normoweight subjects. Plasma ghrelin, insulin, and glucose profiles were determined before and after breakfast and lunch. Obese subjects showed a ghrelin plasma level significantly lower than normoweight subjects (407.3 ⴞ 21.6 vs. 813 ⴞ 72.4 pg/ml, P < 0.01). Patients with LRYGBP

G

HRELIN, A NOVEL PEPTIDE hormone produced primarily by the stomach, has been reported to stimulate food intake in humans (1– 6). Ghrelin seems to promote the production of orexigenic neuropeptides in the hypothalamic arcuate nuclei and activates the neurons that produce these orexigenic neuropeptides, resulting in an increase in feeding and body weight (7–11). These data suggested that the stomach may have an important role in central feeding regulation. Ghrelin is down-regulated in obesity (12), and diet-induced weight loss produces an increase in plasma ghrelin level, suggesting that ghrelin plays a role in the long-term regulation of body weight. Nevertheless, weight loss after gastric bypass has been reported to be associated with markedly suppressed plasma ghrelin levels, suggesting, at least partially, one mechanism involved in long-term weight reduction of this procedure (13). This finding has stimulated a growing interest in the context of surgical treatment of severe obesity. In fact, laparoscopic bariatric surgery is an increasing and effective treatment for morbid obesity (14 –17), yielding satisfactory long-term results in weight loss (18 –22). Several surgical procedures are available for weight loss, and Abbreviations: BMI, Body mass index; CI, confidence interval; CV, coefficient of variation; HOMA-IR, homeostasis model assessment insulin resistance; LASGB, laparoscopic adjustable silicone gastric banding; LRYGBP, laparoscopic Roux-en-Y gastric bypass.

showed baseline ghrelin levels lower than LASGB (213.5 ⴞ 73.9 vs. 314.2 ⴞ 84.3 pg/ml, P ⴝ 0.04). Both groups of patients who underwent bariatric surgical procedures also had ghrelin lower than normoweight and obese subjects (P < 0.01 and P < 0.05, respectively). Patients with total gastrectomy showed plasmatic ghrelin levels extremely lower than those in all other groups (32.6 ⴞ 18.7 pg/ml, P < 0.001 for all). The ghrelin profile in both groups of subjects who underwent LRYGBP and LASGB did not show any meal-related changes as observed in obese and normoweight control groups. Significant difference in plasma ghrelin levels between LRYGBP and LASGB was found, suggesting that both procedures could induce weight loss by different mechanisms in which ghrelin could be involved. (J Clin Endocrinol Metab 88: 4227– 4231, 2003)

they could be differently related to ghrelin pathway. So the aim of this study was the evaluation of ghrelin plasma levels in laparoscopic Roux-en-Y gastric bypass (LRYGBP) and laparoscopic-adjustable silicone gastric banding (LASGB). In addition, we compared these ghrelin values with those obtained in normoweight and obese subjects and patients who had undergone total gastrectomy because no data about ghrelin values after LASGB and total gastrectomy are still available. Subjects and Methods Subjects In this study we selected 43 subjects. We studied 21 obese subjects who underwent laparoscopic bariatric surgery: 10 subjects with LASGB and 11 subjects who underwent LRYGBP. Both procedures were performed from 9 to 15 months before the study. Ten obese subjects matched for body mass index (BMI) to subjects who underwent bariatric surgery, eight patients who had undergone total gastrectomy for gastric cancer, and eight normoweight subjects formed the control groups. All the subjects had stable body weight, as defined by a change of no more than 5% in body weight during the preceding 3 months. No postgastrectomy subjects presented with cancer or cachexia at the time of sampling for ghrelin. Obesity was defined as BMI more than 30 kg/m2. None had any evidence of psychiatric, hepatic, renal, and metabolic diseases, such as diabetes and hypothyroidism, by routine history, physical examination, and laboratory screening tests (fasting glucose, plasmatic creatinine,

4227

4228

J Clin Endocrinol Metab, September 2003, 88(9):4227– 4231

lipids, aspartate aminotransferase, alanine aminotransferase and glutamyl transferase, red and white cell count).

Leonetti et al. • Ghrelin after Bariatric Surgery

Analytical procedures

This was a cross-sectional study. All subjects were admitted to our Day Hospital after fasting overnight. An iv catheter was placed in the arm, and repeated blood samples for plasma ghrelin, insulin, and glucose measurements were performed. After all subjects had a light breakfast (250 g milk and 25 g bread) at 0900 h and lunch at 1300 h (50 g pasta; 70 g bread; 100 g steak; vegetables; and fruit, a macronutrient composition approximating that of the average lunch in Italy). Plasma ghrelin, glucose, and insulin profiles were determined with venous sampling before and after breakfast and lunch at 0900 h, 1000 h, 1100 h, 1300 h, 1400 h, and 1500 h. Samples were stored at 4 C during the collection period, after which plasma was stored at ⫺80 C. This study was conducted in accordance with the guidelines proposed in the Declaration of Helsinki and has been approved by review committee of “ La Sapienza” University. All subjects gave their informed consent before the study began.

Plasma ghrelin was determined in duplicate by RIA kits (ghrelin human RIA kit catalog no. RK-031-30, Phoenix Pharmaceuticals, Belmont, CA). Phoenix’s ghrelin human RIA kit detects full-length, desoctanoyl human ghrelin, including Ser3-octanoyl and Ser3-des-octanoyl ghrelins. Plasma glucose was determined by the glucose oxidase method [autoanalyzer, Beckman Coulter, Inc., Fullerton, CA; coefficient of variation (CV) 1.9 ⫾ 0.2%]. Plasma total cholesterol (CV 3.4 ⫾ 0.2%), high-density lipoprotein cholesterol (CV 3.7 ⫾ 0.4%), and triglyceride (CV 3.1 ⫾ 0.5%) concentrations were measured using enzymatic kits (Ortho-Clinical Diagnostic, Milan, Italy). Blood samples for plasma insulin measurements were collected in heparinized tubes. After centrifugation, plasma insulin concentrations were determined with a commercial RIA kit (CV 3.0 ⫾ 0.3%) (Linco Research, St. Charles, MO). Serum TSH was measured by ultrasensitive assay (immunoradiometric assay, Serono MAIA-clone method, Serono Inc., Rockland, MA). Serum glutamic-oxaloacetic transaminase, serum glutamate pyruvate transaminase, and ␥-glutamyl transpeptidase were measured by standard enzymatic assay analysis using commercially available kits.

Brief description of surgical procedures

Statistical analysis

LASGB. Laparoscopic gastric banding was firstly reported by Belachew et al. in 1993 (23). First, a retrogastric tunnel is created, beginning on the lesser curvature at the of equator of a calibrator tube. The balloon of the calibrator tube is inflated with 25 cc of air and then pulled until the balloon is swinging against the gastroesophageal junction. The retrogastric tunnel is created above the peritoneal reflection of the bursa omentalis. The lap band (INAMED Health BioEnterics Corporation, Santa Barbara, CA) is then passed through this tunnel. The attached silicon tubing is then passed through the buckle of the band until it locks. The anterior wall of the stomach below the band is then secured to the wall above the band with interrupted suture to avoid slippage. The silicone band placed around the upper stomach creates a small pouch with a narrowed outlet. The inner surface of the silicone ring is inflatable and connected by kink-resistant. tubing to the access post, which permits postoperatory percutaneous stoma size adjustment. The pouch fills quickly with solid food and empties slowly to relieve hunger and produce a feeling of fullness.

Data are presented as mean ⫾ sd. Comparisons of clinical parameters before and after bariatric surgery procedures were performed with Mann-Whitney U test with 95% confidence interval (CI). ANOVA followed by multiple comparisons were used to evaluate the differences among the groups with the calculation of 95% CI. Simple linear regression analysis was carried out using standard techniques. Two-tailed P ⬍ 0.05 indicated statistical significance. We used InStat software (GraphPad, San Diego, CA) for statistical analysis.

Experimental protocol

LRYGBP. LRYGBP was first described by Wittgrove and Clark (24). We adopted the technique reported by Gagner. A 15-cc gastric pouch is created and isolated from the distal stomach by several applications of an endo-GIA II linear stapler (Tyco Healthcare, Mansfield, MA). After division of the jejunum 50 cm distal to the ligament of Treitz, the distal limb is anastomized to the isolated gastric pouch (antecolic-antegastric). The gastrojejunostomy is created with a 25 circular stapler. The laterolateral jejunojejunostomy is constructed with standard laparoscopic techniques 100 cm distal to the gastrojejunostomy using endo-GIA II linear stapler (Tyco Healthcare). Gastrectomy. Total gastrectomy with D2 lymphadenectomy plus splenectomy was carried out for gastric cancer (stage II) at least 1 yr before the present study. The reconstruction of the alimentary tract after total gastrectomy was performed using a Roux-en-Y limb (40 cm).

Anthropometric measurements Weight (to the nearest 0.1 kg) and height (to the nearest 0.5 cm) were measured while the subjects were fasting and wearing only their undergarments. BMI was calculated as body weight divided by height squared and was used as a marker of obesity. Waist and hip circumferences (centimeters) were measured, by the same physician, as the widest diameter between the xiphoid process of the sternum and the iliac crest and as the widest diameter over the greater trochanters, respectively.

Measurement of body fat distribution Body composition was evaluated by electrical bioimpedance. Fat-free mass was calculated as the difference between body weight and fat mass.

Results

Anthropometric and clinical characteristics of all subjects studied are summarized in Table 1. No significant difference in age among obese subjects, normoweight subjects, and the groups of patients who underwent surgical procedure was observed. Only patients with total gastric resection were older than other subjects (P ⫽ 0.05). No significant difference in BMI among subjects who underwent LRYGBP and LASGB was found. Patients with total gastrectomy showed a BMI lower than obese subjects and patients who underwent bariatric surgical procedures (P ⬍ 0.01). Clinical and metabolic pattern before and after surgical procedures

Subjects who underwent LRYGBP improved their metabolic pattern after the operation. BMI (P ⬍ 0.001), waist and hip circumferences (P ⫽ 0.004 and P ⬍ 0.001, respectively) decreased. Insulin sensitivity detected by homeostasis model assessment insulin resistance (HOMA-IR) index was significantly improved (P ⬍ 0.001; Table 2) Also, fasting plasma insulin and ␥-glutamyl transpeptidase were lower (P ⫽ 0.002 and P ⫽ 0.05, respectively). Blood pressure, fasting glucose, total cholesterol, and triglycerides showed a trend of lowering after the operation. TABLE 1. Features of all subjects enrolled in the study

Normoweight Obese subjects LRYGBP LASGB Total gastrectomy

n

M/F

Age (yr)

BMI (kg/m2)

8 10 11 10 8

4/4 3/7 2/8 0/10 6/2

40.22 ⫾ 10.56 41.20 ⫾ 11.60 38.70 ⫾ 12.20 41.00 ⫾ 13.60 54.30 ⫾ 12.70

23.00 ⫾ 2.50 35.89 ⫾ 3.60 35.72 ⫾ 2.95 36.03 ⫾ 5.47 21.44 ⫾ 3.57

Leonetti et al. • Ghrelin after Bariatric Surgery

J Clin Endocrinol Metab, September 2003, 88(9):4227– 4231 4229

TABLE 2. Clinical, anthropometric and metabolic features of subjects before and after LRYGBP

2

BMI (kg/m ) Waist (cm) Hip (cm) Glucose (mg/liter) Insulin (mU/liter) HOMA-IR index

Before

After

P

46.43 ⫾ 3.73 130.10 ⫾ 12.03 141.40 ⫾ 5.78 89.54 ⫾ 16.15 20.70 ⫾ 7.53 5.18 ⫾ 2.63

35.72 ⫾ 2.95 112.31 ⫾ 9.60 123.00 ⫾ 5.41 80.30 ⫾ 4.43 9.90 ⫾ 4.16 1.96 ⫾ 0.04

⬍0.001 0.004 ⬍0.001 NS 0.002 ⬍0.001

Data expressed as mean ⫾ SD; comparisons performed with MannWhitney U test, with 95% CI. NS, not significant. TABLE 3. Clinical, anthropometric, and metabolic features of subjects before and after LASGB

BMI (kg/m2) Waist (cm) Hip (cm) Glucose (mg/liter) Insulin (mU/liter) HOMA-IR index

Before

After

P

42.09 ⫾ 4.32 119.80 ⫾ 10.18 129.20 ⫾ 16.16 100.27 ⫾ 19.98 23.09 ⫾ 7.61 4.02 ⫾ 4.66

36.03 ⫾ 5.46 103.00 ⫾ 8.99 120.00 ⫾ 8.44 83.91 ⫾ 4.43 13.33 ⫾ 7.61 3.04 ⫾ 0.04

0.01 0.002 NS 0.02 0.05 0.05

Data expressed as mean ⫾ SD; comparisons performed with MannWhitney U test, with 95% CI. NS, not significant.

In addition, subjects who underwent LASGB improved their metabolic pattern after the operation. BMI (P ⫽ 0.01) and waist circumference (P ⫽ 0.002) decreased. HOMA-IR index also significantly improved (P ⫽ 0.05; Table 3). Diastolic blood pressure, fasting glucose, and plasma insulin were lower than before the operation (P ⫽ 0.05, P ⫽ 0.02, and P ⫽ 0.05, respectively) and systolic blood pressure showed a trend of lowering. Liver studies also tended to improve and TSH remained stable after surgery. Postbariatric surgery plasma ghrelin (Fig. 1)

Obese subjects showed ghrelin plasma levels significantly lower than normoweight subjects (407.3 ⫾ 21.6 vs. 813 ⫾ 72.4 pg/ml, P ⬍ 0.01, ⫺452.6 to ⫺357.5 95% CI). Patients with LRYGBP showed ghrelin levels lower than LASGB (213.5 ⫾ 73.9 vs. 314.2 ⫾ 84.3 pg/ml, P ⫽ 0.04, ⫺170.1 to ⫺31.9 95% CI). Patients with LRYGBP had ghrelin lower than normoweight and obese subjects (P ⬍ 0.01, ⫺710.5 to ⫺607.9 95% CI and P ⬍ 0.05, 263.0 to 124.9 95% CI, respectively). Also patients who underwent LASGB showed plasma ghrelin levels lower than both normoweight and obese subjects (P ⬍ 0.01, ⫺551.4 to ⫺446.4 95% CI; P ⬍ 0.05, ⫺153.0 to ⫺32.1 95% CI, respectively). Patients with total gastrectomy showed plasmatic ghrelin levels extremely lower than those in all other groups (32.6 ⫾ 18.7 pg/ml, P ⬍ 0.001 for all). Plasmatic ghrelin profile (Fig. 2)

In the group of normoweight subjects, plasmatic ghrelin levels rose significantly before breakfast and lunch (P ⬍ 0.05 and P ⬍ 0.005, respectively) and fell significantly after breakfast and lunch (P ⬍ 0.05 and P ⬍ 0.005, respectively). In the group of obese subjects, plasmatic ghrelin levels rose significantly before lunch (P ⬍ 0.05) and fell significantly after lunch (P ⬍ 0.05). No significant difference in plasma ghrelin

FIG. 1. Plasma ghrelin levels at baseline and post bariatric surgery in different groups: normoweight vs. obese subjects (P ⬍ 0.01); LASGB vs. LRYGBP (P ⫽ 0.04); LRYGBP vs. obese subjects (P ⬍ 0.05); LRYGBP vs. normoweight (P ⬍ 0.01); LASGB vs. obese subjects (P ⬍ 0.05); LASGB vs. normoweight (P ⬍ 0.01). Patients with total gastrectomy showed plasmatic ghrelin levels extremely lower than those in all other groups (P ⬍ 0.001 for all; ANOVA with repeated measures with 95% CI).

levels before and after breakfast was observed in the obese group. The ghrelin profile in both groups of subjects who underwent bariatric surgery (LRYGBP and LASGB) and in subjects who had undergone total gastrectomy did not show significant meal-related changes. Insulin profile

Both groups of subjects who underwent LRYGBP and LASGB procedures preserved physiological profile of insulin. Nevertheless, in both groups we observed a weak response of plasma insulin in the first phase after meal (Fig. 3). Correlates of ghrelin

In a univariate linear regression analysis, plasma ghrelin levels were inversely related to BMI in all subjects and taking into account only obese subjects. (r ⫽ ⫺0.48, P ⫽ 0.03 P ⫽ ⫺0.579, and P ⫽ 0.02, respectively). A negative correlation between ghrelin and fasting insulin was found only in the group of obese subjects (r ⫽ ⫺ 0.51, P ⫽ 0.05). No correlation among ghrelin and age, HOMA-IR index, plasma glucose, waist circumference, and fat mass was observed. These correlations were substantially unchanged stratifying for sex. Discussion

Our data showed that plasma ghrelin levels in subjects who underwent laparoscopic gastric bypass were significantly lower than those of subjects with laparoscopic adjustable gastric banding. Taken together, both groups of patients who underwent bariatric procedures had ghrelin lower than normoweight and obese subjects. In addition, patients who had undergone total gastrectomy showed plasma ghrelin levels markedly lower than those in all other groups of patients, strongly indicating that ghrelin is secreted primarily by the stomach. Plasma ghrelin levels rise shortly before and fall shortly after meals only in obese and normoweight subjects. In fact, we have not found a significant change of plasma ghrelin levels in relation to meals in both groups of patient who underwent bariatric surgery. Our findings seem to indicate that both laparoscopic bariatric procedures adopted for the treatment of severe obesity

4230

J Clin Endocrinol Metab, September 2003, 88(9):4227– 4231

Leonetti et al. • Ghrelin after Bariatric Surgery

FIG. 2. Plasma ghrelin profile in all subjects. Plasma ghrelin levels rose significantly before breakfast and lunch (P ⬍ 0.005 for both) and fell significantly after breakfast and lunch (P ⬍ 0.005 for both) in normoweight subjects. In the group of obese subjects, plasma ghrelin levels rose significantly before lunch (P ⬍ 0.05) and fell significantly after lunch (P ⬍ 0.05). There was no significant difference in plasma ghrelin before and after breakfast in the obese group. There were no meal-related ghrelin oscillations in subjects who underwent bariatric surgery (LRYGBP and LASGB) and subjects who had undergone total gastrectomy.

FIG. 3. Plasma insulin profile in obese, LRYGBP, and LASGB subjects. The weak excursion of insulin in the first phase after meal in LRYGBP and LASGB groups is shown.

are characterized by low levels of plasma ghrelin and loss of its physiological oscillation in relation to food (mean follow-up of 12 months). These results could explain, at least in part, the reduction of appetite that occurred mostly in subjects who underwent gastric bypass (25–30). Gastric bypass seems to provide a stronger suppression of ghrelin in comparison with gastric banding procedure. These findings are consistent with the hypothesis that suppression of ghrelin is one mechanism by which gastric bypass can reduce body weight long term, more than gastric banding. Nevertheless, the mechanism by which gastric bypass leads to a reduction in ghrelin levels is still not completely clear. It was advanced by the hypothesis that a permanent absence of food in the empty stomach resulting from gastric bypass could cause a continuous stimulatory signal that ultimately suppresses ghrelin production through a process of overriding inhibition (13). A modification in vagal control of fundus and anthrum cells of the stomach because of a gastric bypass procedure could be involved in paradoxical lowering of ghrelin production. In fact, ghrelin is primarily secreted by neuroendocrine cells of fundus and anthrum of the stomach with the positive control of vagal afferences (1–2). Nevertheless, data on vagal innervation after gastric bypass are controversial. In fact, some studies (31, 32) have indicated that vagal innervation in excluded stomach could be preserved after gastric bypass, whereas others have not. However, ghrelin seems to act differently from other hormones secreted by the stomach (33, 34), and its secretion could be modified by the altered gastrointestinal anatomy. It has been also reported that gastric bypass induces early hormonal changes, despite an unchanged BMI (35), suggesting that this procedure has an endocrine mechanism of action, perhaps

independently of BMI. BMI is crucial in defining the role of ghrelin in weight loss, and a great degree of BMI could influence the results. In this sense we think that an important issue of our study was the evaluation of groups of patients with the same BMI. However, this is not a prospective study and does not indicate causality of the relationship of the procedure to ghrelin levels after surgery. The low levels of ghrelin after gastric banding also could be explained probably by different mechanisms in comparison with the gastric bypass procedure. In fact, laparoscopic adjustable gastric banding even preserving stomach in its anatomical site induces restrictive modification of gastric volume (less the 20 ml) and alteration of peristalsis. The poor amount of food in the stomach could modify its physiological peristalsis, inducing an altered response of ghrelin production. In addition, gastric banding prevents pathologic gastroesophageal reflux but could impair the relaxation of the lower esophageal sphincter, leading to weak esophageal peristalsis (36). Ghrelin exhibited gastroprokinetic activity with structural resemblance to motilin (37), a gut neuropeptide, and its lowering after gastric banding could explain the impaired esophageal peristalsis. Moreover, ghrelin seems to act quite similarly to motilin after gastric banding. In fact, preoperatively, levels of motilin have been also reported to be significantly decreased after gastric banding procedures (38). Ghrelin, also called agent motilin-related peptide, could be part of a family of gastrointestinal hormones linking endocrine control of energy balance with the regulation of gastrointestinal motility (39). In our data plasma ghrelin showed the higher oscillation in response to a meal mainly after lunch in obese subjects. This finding could be explained with the macronutrient composition of a typical Italian breakfast. In fact, our subjects ingested a light breakfast with absence of fat and with a low protein component. This breakfast is different from breakfast in other countries, such as the United States, and suggests our different outcomes. In our data we found a negative correlation between fasting insulin and plasma ghrelin only in obese subjects. This finding was substantially consistent with previous studies reporting a relationship of ghrelin with fasting insulin and/or insulin resistance indices (40, 41). Subjects who underwent bariatric procedures preserved a physiological profile of insulin after the meal. Nevertheless, in both groups no correlation between fasting insulin and ghrelin was found.

Leonetti et al. • Ghrelin after Bariatric Surgery

The weak response of insulin and the loss of physiological ghrelin oscillation at mealtime may be a possible explanation of the lack of this correlation in these subjects. A recent clamp study (42) showed that acute hyperinsulinemia reduces ghrelin levels in healthy people. Nevertheless, future studies will be needed to better address the relationship of ghrelin with insulin in obese subjects and patients who have undergone restrictive gastric procedures. In addition, a significant nadir after meals could have been missed by having 1-h time samples instead of 20- to 30-min timed samples. In conclusion, a significant difference in plasma ghrelin levels between patients who have undergone laparoscopic gastric bypass and laparoscopic adjustable gastric banding was found, suggesting that both procedures could induce weight loss by different mechanisms in which ghrelin could be involved. Acknowledgments Received January 27, 2003. Accepted May 15, 2003. Address all correspondence and requests for reprints to: Frida Leonetti, M.D., Ph.D., Clinica Medica 2, Dipartimento di Scienze Cliniche, Policlinico Umberto I, Viale del Policlinico 155, 00161 Roma, Italy. Email: [email protected].

References 1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656 – 660 2. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141: 4255– 4261 3. Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908 –913 4. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR 2000 The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325– 4328 5. Wren AM, Seal LJ, Cohen MA, Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR 2001 Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992 6. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS 2001 A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714 –1719 7. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194 –198 8. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetitestimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345 9. Maccario M, Tassone F, Grottoli S, Rossetto R, Gauna C, Ghigo E 2002 Neuroendocrine and metaholic determinants of the adaptation ofGH/IGF-1 axis to obesity. Ann Endocrinol (Paris). 63:1404 10. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M 2001 Minireview: ghrelin and the regulation of energy balance—a hypothalamic perspective. Endocrinology 142:163–169 11. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG 2000 Central nervous system control of food intake. Nature 404:661– 671 12. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML 2001 Circulating ghrelin levels are decreased in human obesity. Diabetes 50: 707–709 13. Cummings DE, Weigle DS, Frayo RS 2002 Plasma Ghrelin levels after dietinduced weight loss or gastric by-pass surgery. N Engl J Med 346:1623–1630 14. Livingston EH 2002 Obesity and its surgical management. Am J Surg 184: 103–113 15. Buchwald H 2002 Overview of bariatric surgery. J Am Coll Surg 194:367–375 16. Balsiger BM, Murr MM, Poggio IL, Sarr MG 2000 Bariatric surgery. Surgery for weight control in patients with morbid obesity. Med Clin North Am 84:477– 489

J Clin Endocrinol Metab, September 2003, 88(9):4227– 4231 4231

17. Gentileschi P, Kini S, Catarci M, Gagner M 2002 Evidence-based medicine: open and laparoscopic bariatric surgery. Surg Endosc 16:736 –744 18. Schirmer BD 2000 Laparoscopic bariatric surgery. Surg Clin North Am 80: 1253–1267 19. Angrisani L, Furbetta F, Doldi SB, Basso N, Lucchese M, Giacomelli F, Zappa M, Cosmo L, Veneziani A, Turicchia GU, Alkilani M, Forestieri P, Lesti G, Puglisi F, Toppino M, Campanile F, Capizzi FD, D’Atri C, Sciptoni L, Giardiello C, Lorenzo N, Lacitignola S, Belvederesi N, Marzano B, Bernate P, Iuppa A, Borrelli V, Lorenzo M 2001 Laparoscopic Italian experience with the lap-band. Obes Surg 11:307–310 20. Angrisani L, Furbetta F, Doldi SB, Basso N, Lucchese M, Giacomelli F, Zappa M, Di Cosmo L, Veneziani A, Turicchia GU, Alkilani M, Forestieri P, Lesti G, Puglisi F, Toppino M, Campanile F, Capizzi FD, D’Atri C, Sciptoni L, Giardiello C, Di Lorenzo N, Lacitignola S, Belvederesi N, Marzano B, Bernate P, Iuppa A, Borrelli V, Lorenzo M 2003 Lap band adjustable gastric banding system. Surg Endosc 17:409 – 412 21. Bacci V, Basso MS, Greco F, Lamberti R, Elmore U, Restuccia A, Perrotta N, Silecchia G, Bucci A 2002 Modifications of metabolic and cardiovascular risk factors after weight loss induced by laparoscopic gastric banding. Obes Surg 12:77– 82 22. Silecchia G, Restuccia A, Elmore U, Polito D, Perrotta N, Genco A, Bacci V, Basso N 2001 Laparoscopic adjustable silicone gastric banding: prospective evaluation of intragastric migration of the lap-band. Surg Laparosc Endosc Percutan Tech 11:229 –234 23. Belachew M, Jacqet P, Lardinois F, Karler C 1993 Vertical banded gastroplasty vs. adjustable silicone gastric banding in the treatment of morbid obesity: a preliminary report. Obes Surg 3:275–278 24. Wittgrove AC, Clark GW 1998 Laparoscopic gastric bypass for morbid obesity in a patient with situs inversus. J Laparoendosc Adv Surg Tech A 8:53–55 25. Hell E, Miller KA, Moorehead MK, Norman S 2000 Evaluation of health status and quality of life after bariatric surgery: comparison of standard Roux-en-Y gastric bypass, vertical banded gastroplasty and laparoscopic adjustable silicone gastric banding. Obes Surg 10:214 –219 26. Trostler N, Mann A, Zilberbush N, Avinoach E, Charuzi I 1995 Weight loss and food intake 18 months following vertical banded gastroplasty or gastric bypass for severe obesity. Obes Surg 5:39 –51 27. Halmi KA, Mason E, Falk JR, Stunkard A 1981 Appetitive behavior after gastric bypass for obesity. Int J Obes 5:457– 464 28. Rand CS, Macgregor AM, Hankins GC 1987 Eating behavior after gastric bypass surgery for obesity. South Med J 80:961–964 29. Kenler HA, Brolin RE, Cody RP 1990 Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr 52:87–92 30. Pappas TN 1992 Physiological satiety implications of gastrointestinal antiobesity surgery. Am J Clin Nutr 55:571S–572S 31. Printen KJ, Owensby M 1978 Vagal innervation of the bypassed stomach following gastric bypass. Surgery 84:455– 456 32. Sundbom M, Nyman R, Hedenstrom H, Gustavsson S 2001 Investigation of the excluded stomach after Roux-en-Y gastric bypass. Obes Surg 11:25–27 33. Kellum JM, Kuemmerle JF, O’Dorisio TM, Rayford P, Martin D, Engle K, Wolf L, Sugerman HJ 1990 Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 211:763–771 34. Schrumpf E, Giercksky KE, Nygaard K, Fausa O 1981 Gastrin secretion before and after gastric bypass surgery for morbid obesity. Scand J Gastroenterol 16:721–725 35. Rubino F, Gagner M, Gentileschi P 2002 The effect of Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Gastroenterology 123:44 – 45 36. Weiss HG, Nehoda H, Labeck B, Peer-Kuehberger R, Oberwalder M, Aigner F, Wetscher GJ 2002 Adjustable gastric and esophagogastric banding: a randomized clinical trial. Obes Surg 12:573–578 37. Weiss H, Labeck B, Klocker J, Nehoda H, Mittermair R, Aigner F, Gadenstatter M, Schwelberger H, Wetscher G 2001 Effects of adjustable gastric banding on altered gut neuropeptide levels in morbidly obese patients. Obes Surg 11:735–739 38. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetitestimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345 39. Folwaczny C, Chang JK, Tschop M 2001 Ghrelin and motilin: two sides of one coin? Eur J Endocrinol 144:R1–R3 40. Lucidi P, Murdolo G, Di Loreto C, De Cicco A, Parlanti N, Fanelli C, Santeusanio F, Bolli GB, De Feo P 2002 Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. Diabetes 51: 2911–2914 41. Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R 2002 Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 87:5625– 5629 42. Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A 2003 Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52:16 –20